Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

COVID-19 Updates:      COVID-19 Resources »      Vaccine Update »      Updated Visitor Policy »      What We're Doing to Keep You Safe »

CLINICAL TRIALS
About Clinical Trials Find a Clinical Trial
CLINICAL TRIALS
About Clinical Trials Find a Clinical Trial

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Trial ID or NCT#

NCT02862600

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.

Official Title

A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
View All Criteria

Investigator(s)

Euan A. Ashley
Euan A. Ashley
Cardiologist, Heart failure cardiologist
Associate Dean, School of Medicine, Roger W. and Joelle G. Burnell Professor of Genomics and Precision Health, Professor of Medicine (Cardiovascular Medicine), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology

Contact us to find out if this trial is right for you.

CONTACT

Austin Bland
(650) 725-6911

SEND MESSAGE

View on ClinicalTrials.gov